Page last updated: 2024-09-03

imatinib mesylate and Rupture

imatinib mesylate has been researched along with Rupture in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bjerkehagen, B; Boye, K; Hompland, I; Hølmebakk, T; Stoldt, S1
Deneve, J; Gonzalez, RJ; Han, D1
Ballesteros, J; Pulido, EG; Riquelme, A; Vaz, MÁ1

Reviews

1 review(s) available for imatinib mesylate and Rupture

ArticleYear
Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
    The American surgeon, 2012, Volume: 78, Issue:1

    Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemotherapy, Adjuvant; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Risk Factors; Rupture; Survival Rate

2012

Other Studies

2 other study(ies) available for imatinib mesylate and Rupture

ArticleYear
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
    The British journal of surgery, 2019, Volume: 106, Issue:4

    Topics: Adult; Aged; Databases, Factual; Digestive System Surgical Procedures; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hospitals, University; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Norway; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rupture; Survival Analysis; Treatment Outcome

2019
Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour.
    Anti-cancer drugs, 2012, Volume: 23 Suppl

    Topics: Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Heart Failure; Humans; Imatinib Mesylate; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Rupture; Treatment Outcome

2012